London based Laverock Therapeutics shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencing
- Apr 29, 2025
- 1 min read
CEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in oncology and regenerative medicine.









.png)

